Related Experiment Video
Updated: Nov 1, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Targeted therapy of non-small cell lung cancer
Abstract:
The review article presents the current state and development of the treatment with tyrosine kinase inhibitors in advanced non-small cell lung cancer. It focuses on the therapeutic progress of traditionally targeted gene mutations EGFR, ALK and ROS1, as well as new established or promising targets. Mutations in the BRAF, NTRK, RET, cMET, HER2 and KRAS genes are discussed in this regard. In EGFR mutations, it focuses mainly on possible combination therapy and treatment for mutations in exon 20. In ALK translocation, it points to a new generation of tyrosine kinase inhibitors. In ROS1, the article mentions possible treatment in addition to the usual krizotinib, including the treatment after disease progression. For other genes, the author lists newly approved molecules, or molecules in the promising phase of their development.
Insights
Tyrosine kinase inhibitors offer advanced treatment for non-small cell lung cancer, targeting EGFR, ALK, ROS1, and other gene mutations. New therapies and combination treatments are improving outcomes for patients with advanced lung cancer.
Area of Science:
- Oncology
- Pharmacology
- Genetics
Background:
- Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide.
- Tyrosine kinase inhibitors (TKIs) have revolutionized NSCLC treatment by targeting specific genetic mutations.
- Continuous research is essential to overcome resistance and expand TKI efficacy in advanced NSCLC.
Purpose of the Study:
- To review the current advancements in TKI therapy for advanced non-small cell lung cancer.
- To highlight progress in targeting established mutations (EGFR, ALK, ROS1) and emerging targets.
- To discuss novel therapeutic strategies, including combination therapies and treatments for resistance.
Main Methods:
- Comprehensive literature review of recent studies on TKIs in advanced NSCLC.
- Analysis of clinical trial data and approved therapies for specific genetic mutations.
- Discussion of ongoing research and development of new molecularly targeted agents.
Main Results:
- Significant progress in targeting EGFR mutations, including exon 20 insertions and combination strategies.
- Development of next-generation TKIs for ALK-positive NSCLC, improving efficacy and overcoming resistance.
- Expanded treatment options for ROS1-positive NSCLC beyond crizotinib, including post-progression therapies.
- Emerging TKIs and approved agents for mutations in BRAF, NTRK, RET, cMET, HER2, and KRAS are presented.
Conclusions:
- TKIs represent a cornerstone of personalized medicine in advanced NSCLC.
- Ongoing research into novel targets and combination therapies promises further improvements in patient outcomes.
- The landscape of NSCLC treatment continues to evolve with the development of targeted agents and strategies to manage resistance.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...